69:
27:
291:
synthetic peptides targeting these conserved regions of the HIV p24. Upon immunization with Vacc-4x, potentially followed by reboosting vaccinations, Bionor's researchers are seeking to control virus infection for a longer period of time by exercising the patient's own immune system to seek out and kill virus-producing cells.
294:
In phase II, 134 HIV-infected people from Europe and the US participated in a randomized, placebo-controlled study, where 93 randomly selected people where to receive Vacc-4x and 43 randomly selected people received a placebo injection. The patients were injected with either placebo or Vacc-4x in 28
290:
Vacc-4x aims to generate immune responses to conserved domains, regions of the virus common to all strains of HIV, even if the virus mutates. Persistent immune responses against this part of the virus (the HIV p24 protein) has been shown to delay HIV disease progression. Vacc-4x is made of modified
298:
77 people successfully completed the study (week 52); 25 from the placebo group and 56 from the Vacc-4x group. The placebo group (n=25) had a viral load set point (average of the last two viral load measurements before the end of the study) of 61,900 HIV-RNA/copies/ml (median), compared to the
252:(Nutrilett®, Scan Diet® and NutriPro®), cholesterol reduction (Abacor® and Abalon®) and menopausal and pre-menstrual symptoms (Nutri5®). The marketing and distribution rights for Nutri5 and NutriPro was in 2008 licensed to Nikken Europe for sale in 19 European countries, and in 2009 for
479:
309:
Thirty three patients from USA and four
European countries from the last study with Vacc-4x are taking part at ten clinics. The study was approved in all participating countries in Q4 2012, with startup of patient screening soon after.
281:
Per May, Bionor Pharma has four different vaccine candidates in their product pipeline, from preclinical phase to phase II, leading to phase III which is the last phase before regulatory approval and potential market entry.
475:
417:
389:
450:
299:
Vacc-4x group (n=56) that had a viral load set point of 22,300 HIV-RNA/copies/ml (median). This difference represents a reduction of 64% and is statistically significant (p=0.04).
626:
641:
636:
302:
Bionor Pharma is in the process of conducting two further clinical studies with the Vacc-4x, which can lead towards phase III, which include 1. Vacc-4x in combination with
232:. The company is also a leader in soy technology and has developed patented products for improved health and prevention of lifestyle-related diseases. It was founded by
631:
425:
267:
After the sale of their main brands, the company have moved focus to the vaccine business after the acquisition of biotechnology company Bionor Immuno in 2010.
306:`s immune modulator Revlimid and 2. reboosting patients from the phase II study to investigate whether this can result in a further reduction in viral load.
646:
393:
555:
454:
585:
530:
270:
In 2016, the company was taken over by new investors who pivoted its business from biotech to property management, under the new name Solon.
273:
Since
January 2018, the shareholders unanimously adopted to change the name of the company from Bionor Pharma AS to Bionor Holding AS.
143:
509:
368:
621:
438:
476:"Bionor Pharma announces the acquisition of Solon Eiendom and fully underwritten private placement and subsequent offering"
616:
651:
220:
is a
Norwegian biotechnology company, developing vaccines targeted at rapidly mutating virus infections such as
563:
124:
99:
248:
The company was, under their name Nutri Pharma, formerly known for their soy-based product series within
68:
589:
534:
249:
179:
318:
Other vaccines include humoral, antibody-mediated peptide-based therapeutic HIV-1 vaccine
134:
501:
364:
610:
418:"Nutri5® Distribution Product Supply and Marketing Support Agreement - Bionor Pharma"
257:
47:
37:
26:
324:, that aims to guide the immune system to seek out and kill HIV-infected cells,
261:
225:
120:
116:
237:
155:
233:
229:
303:
112:
390:"Nutri Pharma Patent upheld by European Patent Office - Bionor Pharma"
253:
84:
330:, aiming to treat chronic HCV infection that affects the liver and
167:
204:
80:
221:
502:"Change of name to Bionor Holding AS - Bionor Holding AS"
295:
weeks, followed up by 24 weeks without any injection.
336:, which is in the preclinical phase of development.
199:
189:
177:
165:
153:
141:
130:
108:
104:, Dag Arne Wivelstad, Aslak Aslaksen, Per Bengtsson
90:
76:
61:
53:
43:
33:
412:
410:
260:. The brand Nutrilett was in 2010 sold to the
8:
627:Pharmaceutical companies established in 1993
19:
642:Biotechnology companies established in 1993
637:Companies listed on the Oslo Stock Exchange
16:Norwegian biotechnology company (1993-2017)
240:in protein and lipid research, Lars Høie.
67:
25:
18:
359:
357:
355:
353:
351:
349:
264:-owned health-supplements firm Axellus.
632:Norwegian companies established in 1993
345:
7:
482:from the original on 22 January 2019
365:"Accounting figures Bionor Pharma"
14:
647:Biotechnology companies of Norway
586:"Influenza - Bionor Pharma 2012"
531:"Pipeline - Bionor Pharma 2012"
512:from the original on 2019-04-14
371:from the original on 2019-04-15
1:
668:
185:NOK 203 320 million (2011)
173:NOK 253 395 million (2011)
556:"The HIV Vaccine Vacc-4x"
161:NOK 49 020 million (2011)
149:NOK 46 057 million (2011)
24:
622:Companies based in Oslo
277:Products in development
125:Natural Health Products
137:109.499 million (2011)
478:. 21 November 2016.
422:www.bionorpharma.com
191:Number of employees
21:
617:Vaccine producers
566:on 10 August 2013
506:Bionor Holding AS
250:weight management
218:Bionor Holding AS
215:
214:
103:
20:Bionor Holding AS
659:
652:Norwegian brands
601:
600:
598:
597:
588:. Archived from
582:
576:
575:
573:
571:
562:. Archived from
552:
546:
545:
543:
542:
533:. Archived from
527:
521:
520:
518:
517:
498:
492:
491:
489:
487:
472:
466:
465:
463:
462:
453:. Archived from
447:
441:
436:
430:
429:
424:. Archived from
414:
405:
404:
402:
401:
392:. Archived from
386:
380:
379:
377:
376:
361:
211:
208:
206:
182:
170:
144:Operating income
97:
96:Birger Sørensen
72:
71:
29:
22:
667:
666:
662:
661:
660:
658:
657:
656:
607:
606:
605:
604:
595:
593:
584:
583:
579:
569:
567:
554:
553:
549:
540:
538:
529:
528:
524:
515:
513:
500:
499:
495:
485:
483:
474:
473:
469:
460:
458:
451:"Nyheter - BIA"
449:
448:
444:
437:
433:
416:
415:
408:
399:
397:
388:
387:
383:
374:
372:
363:
362:
347:
342:
316:
288:
279:
246:
203:
192:
178:
166:
158:
146:
123:
119:
115:
93:
66:
17:
12:
11:
5:
665:
663:
655:
654:
649:
644:
639:
634:
629:
624:
619:
609:
608:
603:
602:
577:
547:
522:
508:. 2018-01-29.
493:
467:
442:
431:
428:on 2016-03-03.
406:
381:
344:
343:
341:
338:
315:
312:
287:
284:
278:
275:
245:
242:
213:
212:
207:.bionorholding
201:
197:
196:
193:
190:
187:
186:
183:
175:
174:
171:
163:
162:
159:
154:
151:
150:
147:
142:
139:
138:
132:
128:
127:
110:
106:
105:
94:
91:
88:
87:
78:
74:
73:
63:
59:
58:
57:2 January 1993
55:
51:
50:
45:
41:
40:
35:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
664:
653:
650:
648:
645:
643:
640:
638:
635:
633:
630:
628:
625:
623:
620:
618:
615:
614:
612:
592:on 2014-05-05
591:
587:
581:
578:
565:
561:
560:Bionor Pharma
557:
551:
548:
537:on 2013-05-02
536:
532:
526:
523:
511:
507:
503:
497:
494:
481:
477:
471:
468:
457:on 2016-03-04
456:
452:
446:
443:
440:
435:
432:
427:
423:
419:
413:
411:
407:
396:on 2016-03-04
395:
391:
385:
382:
370:
366:
360:
358:
356:
354:
352:
350:
346:
339:
337:
335:
334:
329:
328:
323:
322:
313:
311:
307:
305:
300:
296:
292:
285:
283:
276:
274:
271:
268:
265:
263:
259:
258:CIS countries
255:
251:
243:
241:
239:
235:
231:
227:
223:
219:
210:
202:
198:
194:
188:
184:
181:
176:
172:
169:
164:
160:
157:
152:
148:
145:
140:
136:
133:
129:
126:
122:
118:
114:
111:
107:
101:
95:
89:
86:
82:
79:
75:
70:
64:
60:
56:
52:
49:
48:Biotechnology
46:
42:
39:
36:
32:
28:
23:
594:. Retrieved
590:the original
580:
568:. Retrieved
564:the original
559:
550:
539:. Retrieved
535:the original
525:
514:. Retrieved
505:
496:
484:. Retrieved
470:
459:. Retrieved
455:the original
445:
434:
426:the original
421:
398:. Retrieved
394:the original
384:
373:. Retrieved
332:
331:
326:
325:
320:
319:
317:
308:
301:
297:
293:
289:
280:
272:
269:
266:
247:
217:
216:
180:Total equity
168:Total assets
77:Headquarters
38:Aksjeselskap
34:Company type
367:. zupa.no.
226:Hepatitis C
121:Health care
117:Soy protein
611:Categories
596:2014-01-07
541:2013-05-04
516:2018-02-25
486:21 January
461:2013-05-03
400:2013-05-03
375:2019-04-15
340:References
238:Dr.philos.
156:Net income
92:Key people
65:2017
234:Cand.med.
230:Influenza
195:18 (2011)
510:Archived
480:Archived
439:HighBeam
369:Archived
333:Vacc-Flu
327:Vacc-HCV
109:Products
44:Industry
570:11 June
321:Vacc-C5
304:Celgene
286:Vacc-4x
200:Website
131:Revenue
113:Vaccine
62:Defunct
54:Founded
314:Others
254:Russia
244:Brands
85:Norway
262:Orkla
572:2013
488:2019
256:and
236:and
228:and
209:.com
81:Oslo
222:HIV
205:www
135:NOK
100:CEO
613::
558:.
504:.
420:.
409:^
348:^
224:,
83:,
599:.
574:.
544:.
519:.
490:.
464:.
403:.
378:.
102:)
98:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
